MX2021016085A - Derivados de benzisoxazol sulfonamida. - Google Patents
Derivados de benzisoxazol sulfonamida.Info
- Publication number
- MX2021016085A MX2021016085A MX2021016085A MX2021016085A MX2021016085A MX 2021016085 A MX2021016085 A MX 2021016085A MX 2021016085 A MX2021016085 A MX 2021016085A MX 2021016085 A MX2021016085 A MX 2021016085A MX 2021016085 A MX2021016085 A MX 2021016085A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- sulfonamide derivatives
- patients
- treatment
- cell growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se relaciona con los compuestos de la fórmula (I)(ver formula) o sales farmacéuticamente aceptables de los mismos, en donde el Anillo A, R1 -R8 , y n se definen en la presente. Los derivados de benzisoxazol sulfonamida novedosos son útiles para el tratamiento de crecimiento celular anormal, tal como cáncer, en pacientes. Las modalidades adicionales relacionadas con las composiciones farmacéuticas que contienen los compuestos y a métodos de utilización los compuestos y composiciones en el tratamiento de crecimiento celular anormal en pacientes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863199P | 2019-06-18 | 2019-06-18 | |
US201962953223P | 2019-12-24 | 2019-12-24 | |
US202063025278P | 2020-05-15 | 2020-05-15 | |
PCT/IB2020/055589 WO2020254946A1 (en) | 2019-06-18 | 2020-06-16 | Benzisoxazole sulfonamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021016085A true MX2021016085A (es) | 2022-04-20 |
Family
ID=71738189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021016085A MX2021016085A (es) | 2019-06-18 | 2020-06-16 | Derivados de benzisoxazol sulfonamida. |
Country Status (29)
Country | Link |
---|---|
US (2) | US11492346B2 (es) |
EP (2) | EP4299135A3 (es) |
JP (2) | JP7352662B2 (es) |
KR (1) | KR20220024671A (es) |
CN (1) | CN114364672A (es) |
AU (2) | AU2020296361A1 (es) |
BR (1) | BR112021025528A2 (es) |
CA (1) | CA3143666A1 (es) |
CL (1) | CL2021003372A1 (es) |
CO (1) | CO2021017504A2 (es) |
CR (1) | CR20210627A (es) |
DK (1) | DK3986890T3 (es) |
EC (1) | ECSP21091615A (es) |
ES (1) | ES2969616T3 (es) |
FI (1) | FI3986890T3 (es) |
HR (1) | HRP20231501T1 (es) |
HU (1) | HUE064683T2 (es) |
IL (1) | IL288802A (es) |
LT (1) | LT3986890T (es) |
MD (1) | MD3986890T2 (es) |
MX (1) | MX2021016085A (es) |
PE (1) | PE20220808A1 (es) |
PL (1) | PL3986890T3 (es) |
PT (1) | PT3986890T (es) |
RS (1) | RS64931B1 (es) |
SI (1) | SI3986890T1 (es) |
TW (1) | TWI787620B (es) |
UY (1) | UY38752A (es) |
WO (1) | WO2020254946A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201810092D0 (en) * | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
RS64931B1 (sr) * | 2019-06-18 | 2023-12-29 | Pfizer | Derivati benzizoxazol sulfonamida |
IL299871A (en) * | 2020-07-15 | 2023-03-01 | Pfizer | Methods and combinations of KAT6 inhibitors for the treatment of cancer |
WO2022187688A1 (en) * | 2021-03-05 | 2022-09-09 | Umbra Therapeutics Inc. | Covalent kras-binding compounds for therapeutic purposes |
WO2022187693A1 (en) * | 2021-03-05 | 2022-09-09 | Umbra Therapeutics Inc. | Covalent cdk2-binding compounds for therapeutic purposes |
EP4341259A1 (en) * | 2021-05-21 | 2024-03-27 | Aurigene Oncology Limited | Fused isoxazolyl compounds as kat6a inhibitors |
EP4368620A1 (en) * | 2021-07-05 | 2024-05-15 | Hangzhou Innogate Pharma Co., Ltd. | Compound serving as kat6 inhibitor |
WO2023016484A1 (zh) | 2021-08-10 | 2023-02-16 | 江苏恒瑞医药股份有限公司 | 磺酰胺衍生物、其制备方法及其在医药上的应用 |
WO2023088233A1 (en) * | 2021-11-16 | 2023-05-25 | Insilico Medicine Ip Limited | Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof |
WO2023114710A1 (en) * | 2021-12-13 | 2023-06-22 | Aurigene Oncology Limited | Fused benzoisoxazolyl compounds as kat6a inhibitors |
TW202400593A (zh) * | 2022-03-28 | 2024-01-01 | 美商艾索司特瑞克斯公司 | Myst家族離胺酸乙醯轉移酶之抑制劑 |
WO2023245150A1 (en) * | 2022-06-16 | 2023-12-21 | Prelude Therapeutics Incorporated | Kat6 targeting compounds with ubiquitin ligase binding moiety |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3064003A (en) | 1962-11-13 | Carboxylic acid derivatives of sub- | ||
US2358031A (en) | 1944-09-12 | Substituted thiadiazoles | ||
US2525321A (en) | 1949-01-07 | 1950-10-10 | American Cyanamid Co | Hydroxybenzenesulfonamidoisoxazoles and preparation of same |
GB689281A (en) | 1950-02-18 | 1953-03-25 | Lunbeck Corp | Improvements in or relating to the production of sulphanilamido-thiadiazoles |
DE1102745B (de) | 1959-06-06 | 1961-03-23 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen |
BE617370A (fr) | 1961-05-09 | 1962-11-08 | Ciba Geigy | Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène |
US3332942A (en) | 1962-11-02 | 1967-07-25 | White Lab Inc | Substituted thiadiazoles |
JPS498255B1 (es) | 1970-10-08 | 1974-02-25 | ||
US3951967A (en) | 1972-03-20 | 1976-04-20 | Merck & Co., Inc. | 7-Mercapto(or thio)-benzothiadiazine products |
US3960854A (en) | 1972-03-20 | 1976-06-01 | Merck & Co., Inc. | 7-Mercapto(or thio)-benzothiadiazine products |
DE2617809C2 (de) | 1976-04-23 | 1984-09-20 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung |
JPS6042794B2 (ja) | 1977-09-27 | 1985-09-25 | 三共株式会社 | イソオキサゾリウム塩,およびその製造方法 |
US4251664A (en) | 1978-05-24 | 1981-02-17 | Henkel Corporation | Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
JPS603685B2 (ja) | 1980-04-15 | 1985-01-30 | 日本コロムビア株式会社 | 絵入りレコ−ド盤の製造方法 |
GB8427618D0 (en) | 1984-11-01 | 1984-12-05 | Shell Int Research | Anticoccidial compositions |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
JPS63238006A (ja) | 1987-03-26 | 1988-10-04 | Shionogi & Co Ltd | イモチ防除剤 |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
FI93954C (fi) | 1988-11-29 | 1995-06-26 | Warner Lambert Co | Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi |
JPH03258771A (ja) | 1990-03-09 | 1991-11-19 | Tosoh Corp | スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤 |
TW224462B (es) | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
FR2690160A1 (fr) | 1992-04-15 | 1993-10-22 | Rhone Poulenc Rorer Sa | Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant. |
NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
EP0626174A3 (en) | 1993-04-21 | 1996-01-03 | Takeda Chemical Industries Ltd | Method and composition for the prophylaxis and / or treatment of underactive organs. |
JP3901229B2 (ja) | 1994-05-13 | 2007-04-04 | Ntn株式会社 | 耐熱・潤滑性樹脂組成物 |
KR100359396B1 (ko) | 1995-04-04 | 2003-03-15 | 텍사스 바이오테크놀로지 코포레이션 | 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체 |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
CA2271116A1 (en) | 1996-11-13 | 1998-05-22 | Gregory J. Wells | Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
BR9812258A (pt) | 1997-04-28 | 2000-07-25 | Texas Biotechnology Corp | Sulfonamidas para tratamento de distúrbios mediados por endotelina |
CN1390206A (zh) | 1999-09-17 | 2003-01-08 | 千嬉药品公司 | 因子Xa的抑制剂 |
AU2456701A (en) | 1999-12-31 | 2001-07-16 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
GB0127344D0 (en) | 2001-11-14 | 2002-01-02 | Cancer Res Ventures Ltd | Assay method |
EP1461327A1 (en) | 2001-11-22 | 2004-09-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
JP2003292485A (ja) | 2002-04-01 | 2003-10-15 | Yamanouchi Pharmaceut Co Ltd | スルホンアミド誘導体 |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
WO2004103980A1 (en) | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
WO2004113310A1 (en) | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
NZ544697A (en) | 2003-07-22 | 2009-03-31 | Janssen Pharmaceutica Nv | Quinolinone derivatives as inhibitors of c-fms kinase |
PE20050358A1 (es) | 2003-08-08 | 2005-05-16 | Vertex Pharma | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje |
US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
NZ554493A (en) | 2004-10-12 | 2009-09-25 | Decode Genetics Ehf | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
CN101218226A (zh) | 2005-05-16 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
WO2007039175A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
WO2007039174A2 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals |
DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
CN101365686A (zh) | 2005-12-21 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的杂环衍生物 |
DK2420494T3 (en) | 2006-08-16 | 2015-01-12 | J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone | Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase |
US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
WO2008063667A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterotricyclic metalloprotease inhibitors |
WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
JP5460589B2 (ja) | 2007-07-13 | 2014-04-02 | アイカジェン, インコーポレイテッド | ナトリウムチャネル阻害物質 |
KR20100092000A (ko) | 2007-11-01 | 2010-08-19 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 아미드 유도체 |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
AU2008340756A1 (en) | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Cyclic pyridyl-N-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
JP5774989B2 (ja) | 2008-08-13 | 2015-09-09 | スメド−ティーエイ/ティーディー・エルエルシー | 整形外科用ねじ |
WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
EP2421833B1 (en) | 2009-04-21 | 2015-01-14 | Nerviano Medical Sciences S.r.l. | Resorcinol derivatives as hsp90 inhibitors |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
WO2011085575A1 (zh) | 2010-01-15 | 2011-07-21 | 江苏省农药研究所股份有限公司 | 邻杂环甲酰苯胺类化合物及其合成方法和应用 |
CN101845043A (zh) | 2010-01-15 | 2010-09-29 | 江苏省农药研究所股份有限公司 | 邻杂环甲酰苯胺类化合物及其合成方法和应用 |
CN101747325A (zh) | 2010-01-15 | 2010-06-23 | 江苏省农药研究所股份有限公司 | 邻杂环甲酰苯胺类化合物及其合成方法和应用 |
CA2797694A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
TW201210597A (en) | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
PL220630B1 (pl) | 2012-12-28 | 2015-11-30 | Inst Immunologii I Terapii Doświadczalnej Pan | Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny |
US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
WO2015102929A1 (en) | 2013-12-30 | 2015-07-09 | Novartis Ag | Tricyclic sulfonamide derivatives |
WO2015112465A1 (en) | 2014-01-24 | 2015-07-30 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2017002120A1 (en) | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
CN107098846B (zh) * | 2016-02-26 | 2020-10-09 | 中国医学科学院药物研究所 | N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途 |
MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
US20220267260A1 (en) * | 2016-11-29 | 2022-08-25 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
GB201810092D0 (en) * | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
RS64931B1 (sr) | 2019-06-18 | 2023-12-29 | Pfizer | Derivati benzizoxazol sulfonamida |
-
2020
- 2020-06-16 RS RS20231177A patent/RS64931B1/sr unknown
- 2020-06-16 MX MX2021016085A patent/MX2021016085A/es unknown
- 2020-06-16 AU AU2020296361A patent/AU2020296361A1/en not_active Abandoned
- 2020-06-16 EP EP23203023.9A patent/EP4299135A3/en active Pending
- 2020-06-16 FI FIEP20743773.2T patent/FI3986890T3/fi active
- 2020-06-16 CR CR20210627A patent/CR20210627A/es unknown
- 2020-06-16 US US16/902,515 patent/US11492346B2/en active Active
- 2020-06-16 PE PE2021002180A patent/PE20220808A1/es unknown
- 2020-06-16 MD MDE20220478T patent/MD3986890T2/ro unknown
- 2020-06-16 EP EP20743773.2A patent/EP3986890B1/en active Active
- 2020-06-16 CA CA3143666A patent/CA3143666A1/en active Pending
- 2020-06-16 CN CN202080057621.7A patent/CN114364672A/zh active Pending
- 2020-06-16 UY UY0001038752A patent/UY38752A/es unknown
- 2020-06-16 DK DK20743773.2T patent/DK3986890T3/da active
- 2020-06-16 PT PT207437732T patent/PT3986890T/pt unknown
- 2020-06-16 JP JP2021574753A patent/JP7352662B2/ja active Active
- 2020-06-16 WO PCT/IB2020/055589 patent/WO2020254946A1/en active Application Filing
- 2020-06-16 LT LTEPPCT/IB2020/055589T patent/LT3986890T/lt unknown
- 2020-06-16 HR HRP20231501TT patent/HRP20231501T1/hr unknown
- 2020-06-16 SI SI202030335T patent/SI3986890T1/sl unknown
- 2020-06-16 HU HUE20743773A patent/HUE064683T2/hu unknown
- 2020-06-16 ES ES20743773T patent/ES2969616T3/es active Active
- 2020-06-16 BR BR112021025528A patent/BR112021025528A2/pt unknown
- 2020-06-16 KR KR1020227001722A patent/KR20220024671A/ko not_active Application Discontinuation
- 2020-06-16 PL PL20743773.2T patent/PL3986890T3/pl unknown
- 2020-06-17 TW TW109120469A patent/TWI787620B/zh active
-
2021
- 2021-12-08 IL IL288802A patent/IL288802A/en unknown
- 2021-12-16 CL CL2021003372A patent/CL2021003372A1/es unknown
- 2021-12-17 EC ECSENADI202191615A patent/ECSP21091615A/es unknown
- 2021-12-21 CO CONC2021/0017504A patent/CO2021017504A2/es unknown
-
2022
- 2022-09-16 US US17/946,101 patent/US20230174522A1/en active Pending
-
2023
- 2023-09-15 JP JP2023149699A patent/JP2023175821A/ja active Pending
- 2023-11-30 AU AU2023274178A patent/AU2023274178A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021016085A (es) | Derivados de benzisoxazol sulfonamida. | |
PH12021551529A1 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
PH12019500329A1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
PH12020551821A1 (en) | Novel compounds | |
MX2021013819A (es) | Compuestos de triarilo para el tratamiento de enfermedades asociadas a pd-l1. | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2021015708A (es) | Compuestos para el tratamiento de enfermedades de pd-l1. | |
EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
MY169142A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
GEP20227434B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
AU2020231934A8 (en) | Compounds useful in HIV therapy | |
WO2021079196A3 (en) | Mettl3 modulators | |
PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
MX2021012491A (es) | Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar. | |
CR20230604A (es) | Inhibidores de mutación de her2 |